التفاصيل البيبلوغرافية
| العنوان: |
An illustrative case of endocardial fibroelastosis and recalcitrant intracardiac thrombosis: a case report. |
| المؤلفون: |
Ozdemir, Denizhan1 (AUTHOR), Cortopassi, Isabel Oliva2 (AUTHOR), McNamara, Robert Lawrence3 (AUTHOR) robert.mcnamara@yale.edu |
| المصدر: |
Thrombosis Journal. 6/7/2019, Vol. 17 Issue 1, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*ATRIAL fibrillation risk factors, *THROMBOSIS prevention, *THROMBOSIS risk factors, *ANTICOAGULANTS, *CARDIOMYOPATHIES, *TREATMENT effectiveness, *RIGHT heart atrium, *DISEASE complications |
| مستخلص: |
Background: Endocardial Fibroelastosis is diffuse, accentuated proliferation of ventricular endocardium causing a rare form of restrictive cardiomyopathy in both children and adults. It is an incompletely understood cause of heart failure predominantly in Sub-Saharan Africa associated with high morbidity and mortality. Atrial fibrillation and thrombus formation are common accompanying complications and portend a poor prognosis. Due to rarity of the condition in the developed countries and lack of evidence based options, the optimal strategy for anticoagulation is unclear. Case presentation: Herein, we describe a relatively asymptomatic patient with endocardial fibroelastosis who has been found to have atrial fibrillation and a large thrombus in the right atrium. Currently, there is no evidence-based strategy in the management of endocardial fibroelastosis-associated intracardiac thrombus. This case report illustrates a scenario by which the use of apixaban potentially benefited or prevented the thrombus formation compared with warfarin as demonstrated by imaging findings. Conclusions: The patients with endocardial fibroelastosis are at risk of developing intracardiac thrombus due to sticky substrate lining cardiac chambers while being relatively asymptomatic. No directed therapy is known for the management of heart failure and any complications of subsequent arrhythmias. The general recommendations follow those of same conditions in other hosts. Novel oral anticoagulant agents can be considered in the treatment of atrial thrombus in the appropriate settings. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder